menu
    • menu

    Company profile for Empress Therapeutics

    Pfanstiehl, a global leader in the manufacture of cGMP high purity, low endotoxin, low metals (HPLE-LM)TM injectable grade excipients.

    Virtual Booth

    Contact Supplier

    Global Pharma Healthcare: Setting the global benchmark in quality, innovation, and care

    Virtual Booth

    Contact Supplier

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    Phyton is a World Leader in Plant Cell Fermentation Technology and Commercial Manufacturing.

    Virtual Booth

    Contact Supplier

    Farmak works in the development, production and marketing of APIs, Intermediates & Specialties// FDA inspected.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Founded by Flagship Pioneering in 2020, Empress has built a proprietary product platform, called Chemilogics, to canvass the untapped universe within the human body of chemistry encoded in DNA and pioneer a new paradigm in small molecule drug discovery with tremendous potential value to patients and society. The company's proprietary bio platform harnesses the power of evolution, human molecular and genetic data, and artificia...
    Founded by Flagship Pioneering in 2020, Empress has built a proprietary product platform, called Chemilogics, to canvass the untapped universe within the human body of chemistry encoded in DNA and pioneer a new paradigm in small molecule drug discovery with tremendous potential value to patients and society. The company's proprietary bio platform harnesses the power of evolution, human molecular and genetic data, and artificial intelligence to discover advanced starting points in endogenous drug-like molecules, helping clinicians to treat a wide range of serious unmet medical needs with small molecule drug candidates.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Empress TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    790 Memorial Drive, Suite 2B Cambridge, MA 02139
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.empresstx.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/empresstx/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Empress Announces Formation of World Leading Scientific Advisory Board
    Empress Announces Formation of World Leading Scientific Advisory Board

    23 Jan 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240123299458/en

    BUSINESSWIRE
    23 Jan 2024
    Share Share
    Empress Therapeutics emerges with $50m to fund small molecule development
    Empress Therapeutics emerges with $50m to fund small molecule development

    21 Jun 2023

    // Aidan McNamee PHARMACEUTICAL TECHNOLOGY

    https://www.pharmaceutical-technology.com/news/empress-therapeutics-emerges-with-50m-to-fund-small-molecule-development/

    Aidan McNamee PHARMACEUTICAL TECHNOLOGY
    21 Jun 2023
    Share Share
    Flagship Pioneering Unveils Empress to Revolutionize Drug Discovery
    Flagship Pioneering Unveils Empress to Revolutionize Drug Discovery

    21 Jun 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/flagship-pioneering-unveils-empress-therapeutics-to-revolutionize-drug-discovery-by-applying-the-power-of-genetics-to-identify-small-molecule-drugs-301853175.html

    PR NEWSWIRE
    21 Jun 2023
    Share Share

    Drugs in Development

    read-more
    read-more
    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Flagship Pioneering Unveils Empress Therapeutics to Revolutionize Drug Discovery by Applying the Power of Genetics to Identify Small Molecule Drugs

    Details:

    The net proceeds will be used to support the development of Empress's proprietary Chemilogics™ product platform which creates potential small molecule medicines and the company's initial pipeline of drug candidates.


    Lead Product(s): Undisclosed

    Therapeutic Area: Immunology Brand Name: Undisclosed

    Study Phase: DiscoveryProduct Type: Undisclosed

    Sponsor: Flagship Pioneering

    Deal Size: $50.0 million Upfront Cash: Undisclosed

    Deal Type: Financing June 21, 2023

    blank

    01

    Empress Therapeutics

    U.S.A
    arrow
    BIO Partnering at JPM
    Not Confirmed

    Empress Therapeutics

    U.S.A
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Undisclosed

    Therapeutic Area : Immunology

    Highest Development Status : Discovery

    Partner/Sponsor/Collaborator : Flagship Pioneering

    Deal Size : $50.0 million

    Deal Type : Financing

    DEALS_DEV arrow-down

    Flagship Pioneering Unveils Empress Therapeutics to Revolutionize Drug Discovery by Applying the P...

    Details : The net proceeds will be used to support the development of Empress's proprietary Chemilogics™ product platform which creates potential small molecule medicines and the company's initial pipeline of drug candidates.

    Product Name : Undisclosed

    Product Type : Undisclosed

    Upfront Cash : Undisclosed

    June 21, 2023

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search